Pembrolizumab combined with carfilzomib and low-dose dexamethasone for relapsed or refractory multiple myeloma: Cohort 2 of the phase I KEYNOTE-023 study

被引：9
|
作者：
Moreau, Philippe [1 ]
Ghori, Razi [2 ]
Farooqui, Mohammed [2 ]
Marinello, Patricia [2 ]
San Miguel, Jesus [3 ]
机构：
[1] Univ Hosp Hotel Dieu, Dept Hematol, Nantes, France
[2] Merck & Co Inc, Dept Med Oncol, Kenilworth, NJ USA
[3] Clin Univ Navarra, CIMA, IDISNA, CIBERONC,Dept Clin & Translat Med, Pamplona, Spain
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2021年 / 194卷 / 01期
关键词：
multiple myeloma; immunotherapy; oncology; IMMUNOTHERAPY;
D O I：
10.1111/bjh.17448
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E48 / E51
页数：4
相关论文
共 50 条
  • [41] A phase 2 study of ibrutinib in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma
    Hajek, Roman
    Pour, Ludek
    Ozcan, Muhit
    Sanchez, Jesus Martin
    Sanz, Ramon Garcia
    Anagnostopoulos, Achilles
    Oriol, Albert
    Cascavilla, Nicola
    Terjung, Andreas
    Lee, Yihua
    Briso, Eva M.
    Dobkowska, Edyta
    Hauns, Bernhard
    Spicka, Ivan
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2020, 104 (05) : 435 - 442
  • [42] A phase I study of vorinostat combined with bortezomib in Japanese patients with relapsed or refractory multiple myeloma
    Yoshiaki Ogawa
    Michinori Ogura
    Kensei Tobinai
    Kiyoshi Ando
    Tatsuya Suzuki
    Takashi Watanabe
    Ken Ohmachi
    Toshiki Uchida
    Mary E. Hanson
    Yoshinobu Tanaka
    Yasuhiro Koh
    Takashi Shimamoto
    Tomomitsu Hotta
    International Journal of Hematology, 2016, 103 : 25 - 33
  • [43] A phase I study of vorinostat combined with bortezomib in Japanese patients with relapsed or refractory multiple myeloma
    Ogawa, Yoshiaki
    Ogura, Michinori
    Tobinai, Kensei
    Ando, Kiyoshi
    Suzuki, Tatsuya
    Watanabe, Takashi
    Ohmachi, Ken
    Uchida, Toshiki
    Hanson, Mary E.
    Tanaka, Yoshinobu
    Koh, Yasuhiro
    Shimamoto, Takashi
    Hotta, Tomomitsu
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2016, 103 (01) : 25 - 33
  • [44] Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results
    Richardson, Paul G.
    Bensinger, William I.
    Huff, Carol Ann
    Costello, Caitlin L.
    Lendvai, Nikoletta
    Berdeja, Jesus G.
    Anderson, Larry D., Jr.
    Siegel, David S.
    Lebovic, Daniel
    Jagannath, Sundar
    Laubach, Jacob P.
    Stockerl-Goldstein, Keith E.
    Kwei, Long
    Clow, Fong
    Elias, Laurence
    Salman, Zeena
    Graef, Thorsten
    Bilotti, Elizabeth
    Vij, Ravi
    BRITISH JOURNAL OF HAEMATOLOGY, 2018, 180 (06) : 821 - 830
  • [45] Carfilzomib-dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: secondary analysis of the phase 3 ENDEAVOR study
    Goldschmidt, Hartmut
    Moreau, Philippe
    Ludwig, Heinz
    Niesvizky, Ruben
    Chng, Wee-Joo
    Joshua, Douglas
    Weisel, Katja
    Spencer, Andrew
    Orlowski, Robert Z.
    Feng, Shibao
    Iskander, Karim S.
    Dimopoulos, Meletios A.
    LEUKEMIA & LYMPHOMA, 2018, 59 (06) : 1364 - 1374
  • [46] A phase 2 trial of the efficacy and safety of elotuzumab in combination with pomalidomide, carfilzomib and dexamethasone for high-risk relapsed/refractory multiple myeloma
    Yashar, David
    Spektor, Tanya M.
    Martinez, Daisy
    Ghermezi, Matthew
    Swift, Regina A.
    Eades, Benjamin
    Schwartz, Gary
    Eshaghian, Shahrooz
    Lim, Stephen
    Vescio, Robert
    Berenson, James R.
    LEUKEMIA & LYMPHOMA, 2022, 63 (04) : 975 - 983
  • [47] A Phase 2 Trial of the Efficacy and Safety of Elotuzumab in Combination with Pomalidomide, Carfilzomib and Dexamethasone for High Risk Relapsed/Refractory Multiple Myeloma Patients
    Berenson, James
    Martinez, Daisy
    Spektor, Tanya
    Sanchez, Armando
    Ghermezi, Matthew
    Swift, Regina
    Eades, Benjamin
    Schwartz, Gary
    Eshaghian, Shahrooz
    Lim, Stephen
    Vescio, Robert
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10) : E249 - E250
  • [48] Phase I study of once weekly treatment with bortezomib in combination with lenalidomide and dexamethasone for relapsed or refractory multiple myeloma
    Haruhito Totani
    Masaki Ri
    Chie Kato
    Takahiro Nakashima
    Nana Suzuki
    Shinya Hagiwara
    Takashi Kanamori
    Satsuki Murakami
    Arisa Masuda
    Shiori Kinoshita
    Takashi Yoshida
    Tomoko Narita
    Asahi Ito
    Shigeru Kusumoto
    Takashi Ishida
    Hirokazu Komatsu
    Shinsuke Iida
    International Journal of Hematology, 2016, 103 : 316 - 321
  • [49] Phase I study of once weekly treatment with bortezomib in combination with lenalidomide and dexamethasone for relapsed or refractory multiple myeloma
    Totani, Haruhito
    Ri, Masaki
    Kato, Chie
    Nakashima, Takahiro
    Suzuki, Nana
    Hagiwara, Shinya
    Kanamori, Takashi
    Murakami, Satsuki
    Masuda, Arisa
    Kinoshita, Shiori
    Yoshida, Takashi
    Narita, Tomoko
    Ito, Asahi
    Kusumoto, Shigeru
    Ishida, Takashi
    Komatsu, Hirokazu
    Iida, Shinsuke
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2016, 103 (03) : 316 - 321
  • [50] Ibrutinib, lenalidomide and dexamethasone in patients with relapsed and/or refractory multiple myeloma: Phase I trial results
    Ailawadhi, Sikander
    Parrondo, Ricardo D.
    Moustafa, Muhamad Alhaj
    LaPlant, Betsy R.
    Alegria, Victoria
    Chapin, Dustin
    Roy, Vivek
    Sher, Taimur
    Paulus, Aneel
    Chanan-Khan, Asher A.
    HEMATOLOGICAL ONCOLOGY, 2022, 40 (04) : 695 - 703
12345